RGTLF (Argent Biopharma) Buyback Yield %: -150.89 (As of Jun. 28, 2026)


What is Argent Biopharma Buyback Yield %?

Argent Biopharma RGTLF Buyback Yield % is -150.89 as of Jun. 28, 2026. The stock has 8 warning signs investors should review. Among 292 Drug Manufacturers companies, Argent Biopharma ranks worse than 98.29% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Argent Biopharma's current buyback yield was -150.89%.

Argent Biopharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Argent Biopharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Buyback Yield % Chart

Argent Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.65 -20.13 -13.11 -104.24 -183.54

Argent Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.38 -111.19 -57.00 -177.86 -106.27

RGTLF vs ZTS, UTHR: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Argent Biopharma Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Buyback Yield % falls into.


Argent Biopharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Argent Biopharma's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 6.77) / 3.6885513
=-183.54%

Argent Biopharma's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0.101 + 3.941) / 4.586175
=-88.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -150.89 mean?
Argent Biopharma (RGTLF) has a Buyback Yield % of -150.89 as of Jun. 28, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Argent Biopharma and its competitors. According to the industry distribution chart, Argent Biopharma ranks #287 out of 292 companies in the Drug Manufacturers industry, placing it in the top 98.3%.
Is Argent Biopharma's Buyback Yield % too high?
Argent Biopharma's current Buyback Yield % is -150.89. Based on the distribution chart, Argent Biopharma ranks #287 out of 292 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #287 out of 292 companies for Buyback Yield %. This places Argent Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Argent Biopharma and its competitors. Argent Biopharma's current Buyback Yield % is -150.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Buyback Yield % is -150.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Buyback Yield % is -150.89 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.